UI Hospitals and Clinics
A Phase 11 Study to Evaluate the Efficacy and Safety of 12 weeks Treatment With Oral CNDO 210 Trichuris Suis Ova Suspension(TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients with Moderatley to Severly Active Crohn's Disease(TRUST 1)
The Objective of this Phase II study is to evaluate the efficacy and safety of 12 weeks of treatment with oral CNDO 201 Trichuris suis ova suspension (TSO) as compared to placebo, followed by a 12 week open-label treatment period in patients with moderately to severely active Crohn’s disease.
Dr. Steven Polyak 319-353-8574
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.